Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Our CEO, Nello Mainolfi, provides an overview of Kymera’s approach, pipeline, and upcoming milestones.
Our CEO, Nello Mainolfi, was interviewed by Nature Reviews Drug Discovery to discuss how targeted protein degradation can unlock previously intractable disease targets, including our STAT6 and IRAK4 degraders in immunology.